Background. In humans and nonhuman primates, Ebola virus causes a virulent viral
hemorrhagic fever for which no licensed vaccines or therapeutic drugs exist. In the present …

Background. Outbreaks of filoviral hemorrhagic fever occur sporadically and unpredictably
across wide regions in central Africa and overlap with the occurrence of other infectious …

Ebola virus (EBOV) infections cause lethal hemorrhagic fever in humans, resulting in up to
90% mortality. EBOV outbreaks are sporadic and unpredictable in nature; therefore, a …

Background The worst Ebola virus disease (EVD) outbreak in history has resulted in more
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …

The Ebola virus (EBOV) epidemic in West Africa increased the focus on vaccine
development against this hemorrhagic fever–causing pathogen, and as a consequence …

The recent Ebola virus (EBOV) epidemic in West Africa demonstrates the potential for a
significant public health burden caused by filoviral infections. No vaccine or antiviral is …

The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the
progress of several vaccines and antivirals through clinical trials, including the replication …

Background The Ebola virus is transmitted by direct contact with bodily fluids of infected
individuals, eliciting death rates as high as 90% among infected humans. Currently …

Abstract For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Cô te d'Ivoire,
and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed …

Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as
an emerging/re-emerging virus and as a potential biological weapon. Substantial progress …